Gerding MN, van der Zant FM, van der Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves’ophthalmopathy[J]. Clin Endocrinol, 1999, 50: 373-379.
[3]
Marcocci C, Marino M, Rocchi R, et al. Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy[J]. J Endocrinol Invest, 2004, 27: 272-280.
[4]
Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals[J]. J Nucl Med, 1990, 31: 1 501-1 509.
Many MC, Costagliola S, Detrait M, et al. Development of an Animal Model of Autoimmune Thyroid Eye Disease[J]. J Immunol, 1999, 162: 4 966-4 974.
[7]
胡蜀红. Graves眼病的发病机理[J].国外医学：内分泌学分册，2002，22：98-101.
[8]
Hiromatsu Y, Yabg D, Bednarczuk T , et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy[J]. J Clin Endocrinol Metab, 2000, 85( 3): 1 194-1 199.
